103 results found.

Type 2 Diabetes Mellitus Clinical Trial using MK-3102; Placebo to MK-3102; Glipizide; Placebo to glipizide; Insulin

Merck Sharp & Dohme Corp. - Recruiting 30 years or older.
- A Phase III, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects With Type 2 Diabetes Mellitus With Moderate or Severe Chronic Kidney Disease or Kidney Failure on Dialysis Who Have Inadequate Glycemic Control.
MK-3102; Placebo to MK-3102; Glipizide; Placebo to glipizide; Insulin

Glomerulonephritis, Lupus Nephritis, Membranous Glomerulonephriti Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 5 years or older.
- Studies of Immunologically-Mediated Kidney Diseases.

Autosomal Dominant Polycystic Kidney Disease Clinical Trial using Octreotide-LAR; Saline solution.

Mario Negri Institute for Pharmacological Research - Recruiting 18 years to 75 years.
- A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFECTS OF LONG-ACTING SOMATOSTATIN (OCTREOTIDE LAR) THERAPY ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE TO SEVERE RENAL INSUFFICIENCY.
Octreotide-LAR; Saline solution.

Patients Undergoing Surgery for Congenital Heart Disease Clinical Trial using surgery for congenital heart disease

Samsung Medical Center - Recruiting N/A to 10 years.
- Incidence, Risk Factors, and Risk Model of Acute Kidney Injury in Pediatric Patients Who Undergoing Surgery for Congenital Heart Disease.
surgery for congenital heart disease

Management of Anemia in Chronic Kidney Disease Patients Not on Di Clinical Trial using Darbepoetin alfa

Amgen - Recruiting 18 years or older.
- Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease.
Darbepoetin alfa

Secondary Hyperparathyroidism; Chronic Kidney Disease Clinical Trial using AMG 416; cinacalcet

Amgen - Recruiting 18 years to 85 years.
- A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism.
AMG 416; cinacalcet

Hyperparathyroidism, Secondary Clinical Trial using AMG 416

Amgen - Recruiting 18 years or older.
- A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis.
AMG 416

Kidney Disease, Nephrotic Syndrome, Glomerular Disease, Glomerulo Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- The Nephrotic Syndrome Study Network (NEPTUNE).

Diabetic Nephropathy Clinical Trial using Repository Corticotropin Injection; Placebo

Questcor Pharmaceuticals, Inc. - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Design Pilot Safety and Efficacy Study of H.P. Acthar Gel (Acthar) in Patients With Diabetic Nephropathy and Proteinuria..
Repository Corticotropin Injection; Placebo

Cytomegalovirus Infections Clinical Trial using RG7667; Placebo

Genentech - Recruiting 18 years or older.
- A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of RG7667 for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients.
RG7667; Placebo

Anemia, or Kidney Failure, Chronic Clinical Trial using Sotatercept

Celgene Corporation - Recruiting 18 years or older.
- A Phase 2 Multicenter, Randomized, Open-Label , Multiple-Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects With End-Stage Kidney Disease on Hemodialysis Switched From Erythropoiesis Stimulating Agents With Staggered Dose Group Escalation in Part 1 Followed by a Parallel Group, Active Controlled Study of Selected Dose(s) and Regimen(s) in Part 2: To Evaluate the Pharmacokinetics, Safety, Tolerability, Efficacy, Dosing Regimen, and Pharmacodynamics of Sotatercept.
Sotatercept

Acute Renal Failure, Kidney Disease, or Coronary Artery Disease Clinical Trial using IV isotonic saline; IV isotonic bicarbonate; N-acetylcysteine; Placebo

Department of Veterans Affairs - Recruiting 18 years or older.
- CSP #578 - Prevention of Serious Adverse Outcomes Following Angiography.
IV isotonic saline; IV isotonic bicarbonate; N-acetylcysteine; Placebo

Diabetic Kidney Disease Clinical Trial using baricitinib; Placebo

Eli Lilly and Company - Recruiting 18 years or older.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY3009104 in Patients With Diabetic Kidney Disease.
baricitinib; Placebo

Arteriovenous Graft Clinical Trial using SRM003; Participating Site's standard practice

Shire Development LLC - Recruiting 18 years or older.
- A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugelr) in the Treatment of Subjects With Vascular Injury Resulting From Arteriovenous Graft Surgery for Hemodialysis Access.
SRM003; Participating Site's standard practice

Arteriovenous Fistula Clinical Trial using SRM003; Participating Site's standard practice

Shire Development LLC - Recruiting 18 years or older.
- A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugelr) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access.
SRM003; Participating Site's standard practice

End Stage Renal Disease, Kidney Disease, or Protein Energy Wastin Clinical Trial using PINTA 745; Placebo

Pinta Biotherapeutics - Recruiting 18 years to 85 years.
- A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting.
PINTA 745; Placebo

Chronic Kidney Disease Clinical Trial using Structured Exercise

Department of Veterans Affairs - Recruiting 18 years or older.
- Structured Exercise in Obese Diabetic Patients With Chronic Kidney Disease.
Structured Exercise

Chronic Kidney Disease, or Acute Kidney Injury Clinical Trial using 75 mg / 6 mL VFIT

FAST BioMedical - Recruiting 19 years to 75 years.
- A Single-Center Prospective Study Evaluating the FAST Measured Glomerular Filtration Rate (mGFR) TestT in Adults With Preserved Kidney Function and Impaired Kidney Function With Comparison to Iohexol Clearance Methods.
75 mg / 6 mL VFIT

Heart Failure Clinical Trial using BAY94-8862; Eplerenone; Placebo

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of BAY94-8862 in Japanese Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone Versus Eplerenone.
BAY94-8862; Eplerenone; Placebo

Hypertension, or Chronic Kidney Disease Clinical Trial using Valsartan

Novartis - Recruiting 6 years to 17 years.
- A Multicenter, Open-label, 18 Month Study to Evaluate the Long-term Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age With Hypertension and With or Without Chronic Kidney Disease.
Valsartan

Chronic Kidney Disease Clinical Trial using No intervention

Janssen Inc. - Recruiting 18 years or older.
- A Prospective, Observational, Randomized Comparative Study of Case Managed Versus Non-case Managed Initiation of Hemodialysis.
No intervention

Liver Disease, or Renal Disease Clinical Trial

Baylor Research Institute - Recruiting 18 years or older.
- Quantitative Evaluation of Liver and Kidney Disease With Liver and Kidney Elastography Measurements in Liver Transplant Recipients Using the Supersonic Imagine Aixplorer ShearWaveTM Elastography Ultrasound Machine.

Kidney Disease, Kidney Transplantation, or Kidney Failure, Chroni Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Role of Donor Genetics and Recipient Genetics in Kidney Transplant Outcomes.

Renal Cancer, or Von Hippel Lindau Clinical Trial using ZACTIMA (Vandetanib) (ZD6474)

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase 2 Study of ZD6474 (Vandetanib) in Patients With Von Hippel Lindau Disease and Renal Tumors.
ZACTIMA (Vandetanib) (ZD6474)

Albinism, Intestinal Disease, Kidney Disease, Myocardial Disease, Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 1 year to 80 years.
- Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome.

Syndrome Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- The Birt Hogg-Dube Syndrome: Identification of the Disease Gene and Characterization of the Predisposition of Renal Cancer.

Renal Cell Carcinoma, Graft-Versus-Host Disease, or Engraftment S Clinical Trial using Pentostatin; Sirolimus; Cyclophosphamide; Allogeneic Hematopoietic Stem Cell Transplant; Th2 Cell Transplantation; Th2 Cells in Allogeneic HSCT

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 75 years.
- Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells.
Pentostatin; Sirolimus; Cyclophosphamide; Allogeneic Hematopoietic Stem Cell Transplant; Th2 Cell Transplantation; Th2 Cells in Allogeneic HSCT

Anemia, or Chronic Kidney Disease Clinical Trial using AKB-6548; Placebo

Akebia Therapeutics - Recruiting 18 years to 82 years.
- Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis).
AKB-6548; Placebo

Anemia Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- An Observational, Prospective Study to Evaluate the Hemoglobin Levels in Non-dialysis Chronic Kidney Disease Subjects With Renal Anaemia, Treated With MIRCERAr (Methoxy-polyethylene-glycol-epoetin Beta) (OPTIMA)..

Kidney Disease, Chronic Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Non Interventional Study to Assess the Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CDK) Patients Not in Dialysis Treated With Mircera.

Anemia, or Renal Insufficiency, Chronic Clinical Trial using BAY85-3934; Darbepoetin alfa

Bayer - Recruiting 18 years or older.
- A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Darbepoetin Alfa) in the Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment in Europe and Asia Pacific.
BAY85-3934; Darbepoetin alfa

End Stage Kidney Disease Clinical Trial using Website Intervention

Northwestern University - Recruiting 18 years or older.
- Evaluation of a Culturally Competent Website on Living Kidney Donation for Hispanics.
Website Intervention

Kidney Transplant Recipient Clinical Trial using 64-slice Multidetector coronary CT angiography

Yonsei University - Recruiting 40 years or older.
- .
64-slice Multidetector coronary CT angiography

End-stage Kidney Disease Clinical Trial using Inform Me: web-based education tool

Northwestern University - Recruiting 21 years or older.
- Optimizing Kidney Transplant Patients' Informed Consent for Increased Risk Donors.
Inform Me: web-based education tool

Anaemia Clinical Trial using GSK1278863; Placebo; rhEPO

GlaxoSmithKline - Recruiting 18 years or older.
- A Phase IIB, Randomized, Blinded, Dose-ranging, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Dose Response Relationship of GSK1278863 Over the First 4 Weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 Over 24 Weeks in Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Switch From Recombinant Human Erythropoietin.
GSK1278863; Placebo; rhEPO

Chronic Kidney Disease, Chronic Kidney Insufficiency, Chronic Ren Clinical Trial using Facilitated Clinical Decision Support; Clinical Decision Support Only

American Academy of Family Physicians - Recruiting 18 years or older.
- Improving Evidence-Based Primary Care for Chronic Kidney Disease.
Facilitated Clinical Decision Support; Clinical Decision Support Only

Anaemia Clinical Trial using GSK1278863; Placebo

GlaxoSmithKline - Recruiting 20 years or older.
- A 4-Week, Phase II, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease.
GSK1278863; Placebo

Adult Polycystic Kidney Disease Clinical Trial using renal denervation

Odense University Hospital - Recruiting 18 years or older.
- .
renal denervation

Type 2 Diabetes Mellitus Clinical Trial using Ertugliflozin; Placebo

Merck Sharp & Dohme Corp. - Recruiting 25 years or older.
- A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Background Antihyperglycemic Therapy.
Ertugliflozin; Placebo

Renal Impairment, Renal Insufficiency, Kidney Disease, or Kidney Clinical Trial using IDN-6556

Conatus Pharmaceuticals Inc. - Recruiting 18 years to 75 years.
- An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Severe Renal Impairment and in Matched Healthy Volunteers.
IDN-6556

IgA Glomerulonephritis Clinical Trial using methylprednisolone; Placebo,

The George Institute - Recruiting 14 years or older.
- Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study.
methylprednisolone; Placebo,

Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymph Clinical Trial using Haploidentical Bone Marrow/Kidney

Massachusetts General Hospital - Recruiting 18 years to 70 years.
- Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders.
Haploidentical Bone Marrow/Kidney

Hyperphosphataemia in Chronic Kidney Disease Clinical Trial using Lanthanum carbonate; Calcium carbonate

Shire Development LLC - Recruiting 6 Months to 17 years.
- A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Compare the Efficacy, Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate Using a Crossover Design and Investigate the Efficacy and Safety of 12 Months of Treatment With Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents Aged 6 Months to <18 Years With Chronic Kidney Disease on Dialysis.
Lanthanum carbonate; Calcium carbonate

Nervous System, Diabetic Kidney Disease, or Diabetes Mellitus, Ty Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Determinants of Diabetic Nephropathy in American Indians.

Hemodialysis, or Hyperphosphatemia Clinical Trial using Lanthanum Carbonate; Calcium Carbonate

Translational Research Informatics Center, Kobe, Hyogo, Japan - Recruiting N/A or older.
- Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate on Cardiovascular Mortality and Morbidity in Patients With Chronic Kidney Disease on Hemodialysis (CKD5D).
Lanthanum Carbonate; Calcium Carbonate

Chronic Kidney Disease Clinical Trial using Storage of kidney in refrigerated solution; Kidney perfused by pulsatile machine

Mario Negri Institute for Pharmacological Research - Recruiting 50 years or older.
- A PROSPECTIVE STUDY TO COMPARE EARLY GRAFT FUNCTION OF RECIPIENTS OF SINGLE OR DUAL KIDNEY ORGANS STORED IN ICE COLD SOLUTION OR PULSED PERFUSION.
Storage of kidney in refrigerated solution; Kidney perfused by pulsatile machine

End-stage Kidney Disease, or End-stage Renal Disease Clinical Trial using Optiflow

Bioconnect Systems, Inc - Recruiting 18 years to 75 years.
- The 'OPEN' Study Optiflow PatEncy and MaturatioN.
Optiflow

Anemia Clinical Trial using methoxy polyethylene glycol-epoetin beta [Mircera]

Hoffmann-La Roche - Recruiting 5 years to 17 years.
- An Open Label Multi-center, Multiple Dose Study to Determine the Optimum Starting Dose of Intravenous MIRCERA for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis..
methoxy polyethylene glycol-epoetin beta [Mircera]

Chronic Kidney Disease, or Type 2 Diabetes Mellitus Clinical Trial using AZD1722; Placebo

Ardelyx - Recruiting 18 years to 80 years.
- An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria.
AZD1722; Placebo

Anemia, or Chronic Kidney Disease Clinical Trial using Darbepoetin alfa

Amgen - Recruiting N/A to 1 year.
- An Open-label, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Darbepoetin Alfa in Paediatric Subjects From Birth to Less Than 1 Year of Age With Anemia Due to Chronic Kidney Disease.
Darbepoetin alfa

Anemia, or Renal Insufficiency, Chronic Clinical Trial using BAY85-3934; Epoetin alfa/beta

Bayer - Recruiting 18 years or older.
- A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan.
BAY85-3934; Epoetin alfa/beta

Anemia, Kidney Disease, Chronic Clinical Trial using methoxy polyethylene glycol-epoetin beta [Mircera]

Hoffmann-La Roche - Recruiting 18 years or older.
- Comparative Study to Assess the Effect of the Altitude on Dose Requirements of Methoxy Polyethylene Glycol-epoetin Beta to Correct Haemoglobin Levels in Chronic Renal Anemia in Pre-dialysis and Dialysis Patients.
methoxy polyethylene glycol-epoetin beta [Mircera]

Anemia Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Study on the Use of Mircera in the Treatment of Chronic Renal Anemia in Patients With Chronic Kidney Disease Stages III-IV Not on Dialysis and in Patients on Stage V on Hemodialysis.

Heart Failure Clinical Trial using BAY94-8862; Placebo; Inspra (eplerenone)

Bayer - Recruiting 18 years or older.
- A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone.
BAY94-8862; Placebo; Inspra (eplerenone)

Anemia Clinical Trial using methoxy polyethylene glycol-epoetin beta [Mircera]; ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Open Label Study to Assess All-cause Mortality and Cardiovascular Morbidity in Patients With Chronic Kidney Disease on Dialysis and Those Not on Renal Replacement Therapy Under Treatment With Mircera or Reference ESAs..
methoxy polyethylene glycol-epoetin beta [Mircera]; ESAs (darbepoetin alfa, epoetin alfa or epoetin beta)

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Clinical Trial using Lanreotide

University Medical Centre Groningen - Recruiting 18 years to 60 years.
- The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD.
Lanreotide

Autosomal Recessive Polycystic Kidney Disease, Congenital Hepatic Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 6 Months to 80 years.
- Clinical and Molecular Investigations Into Ciliopathies.

Hyperphosphatemia, or Kidney Disease Clinical Trial using Fosrenol (Lanthanum Carbonate, BAY77-1931)

Bayer - Recruiting N/A or older.
- Drug Use Investigation of Fosrenol for Hyperphosphatemia With Chronic Kidney Disease Not on Dialysis.
Fosrenol (Lanthanum Carbonate, BAY77-1931)

Chronic Kidney Disease Clinical Trial using aerobic and resistance training; aerobic combined with balance training

Region Skane - Recruiting 18 years or older.
- Long-term Effects of Basic Aerobic Training Combined With Either Resistance - or Balance Training in CKD Patients - a Comparative Study.
aerobic and resistance training; aerobic combined with balance training

Chronic Kidney Disease Clinical Trial

University of California, San Francisco - Recruiting 18 years to 90 years.
- Endothelial Function and Arterio-Venous Fistula Maturation.

Chronic Kidney Disease (CKD) Clinical Trial using CKD Registry; ATSM + Health Coach; Usual care

University of California, San Francisco - Recruiting 18 years or older.
- The Kidney Awareness Registry and Education Study.
CKD Registry; ATSM + Health Coach; Usual care

Kidney Diseases, or Glomerulosclerosis, Focal Clinical Trial using Kidney needle biopsy; DEXA Scan; X-rays; Retinoids for Podocyte Disease

National Institutes of Health Clinical Center (CC) - Recruiting 16 years or older.
- Retinoids for Podocyte Disease.
Kidney needle biopsy; DEXA Scan; X-rays; Retinoids for Podocyte Disease

Leiomyomatosis, or Kidney Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer.

Vesicoureteral Reflux, Renal Hypodysplasia, Nonsyndromic, 1, or C Clinical Trial using nitrofurantoin; No prophylaxis; Amoxicillin-Potassium Clavulanate Combination; Trimethoprim/sulfamethoxazole; Cefixime

Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi - Recruiting 1 Month to 4 Months.
- Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract.
nitrofurantoin; No prophylaxis; Amoxicillin-Potassium Clavulanate Combination; Trimethoprim/sulfamethoxazole; Cefixime

Kidney Disease Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 7 years or older.
- Determination of Glomerular Filtration Rate, Effective Renal Plasma Flow and Glomerular Capillary Wall Permselectivity.

Chronic Kidney Disease Clinical Trial using The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access

TVA Medical Inc. - Recruiting 18 years or older.
- Novel Endovascular Access Trial (NEAT): A Study of the FLEX System for Percutaneous AV Fistula Creation in Hemodialysis Patients.
The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access

End-stage Renal Disease, or Kidney Failure, Chronic Clinical Trial using HAVG graft implantation

Humacyte, Inc. - Recruiting 18 years to 75 years.
- A Pilot Study for Evaluation of the Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease.
HAVG graft implantation

Chronic Kidney Failure Clinical Trial using Boost High Protein

Texas A&M University - Recruiting 55 years or older.
- Chronic Kidney Disease in Relation to Alterations in Protein and Amino Acid Metabolism and Function.
Boost High Protein

Polycystic Kidney, Autosomal Dominant Clinical Trial using KD019

Kadmon Corporation, LLC - Recruiting 18 years to 55 years.
- A Phase 1b/2a, Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease.
KD019

Chronic Kidney Diseases, or Chronic Kidney Insufficiency Clinical Trial using general management; self-management; peer-assisted management

China Medical University Hospital - Recruiting 20 years to 85 years.
- The Cost Effectiveness and Evaluation of Disease Management of Chronic Kidney Disease and High Risk Population.
general management; self-management; peer-assisted management

Metabolic Acidosis, or Chronic Kidney Disease Clinical Trial using Sodium bicarbonate; Control

University of Colorado, Denver - Recruiting 40 years to 70 years.
- Effect of Treatment of Metabolic Acidosis on Vascular Function in Patients With Chronic Kidney Disease: A Pilot Study.
Sodium bicarbonate; Control

Chronic Kidney Disease Clinical Trial using Conventional low protein diet; Very low protein diet supplemented with Ketosteril

Anemia Working Group Romania - Recruiting 18 years to 85 years.
- Effect of Very Low Protein Diet Supplemented With Ketoanalogues of the Essential Amino Acids on the Progression of Chronic Kidney Disease.
Conventional low protein diet; Very low protein diet supplemented with Ketosteril

End Stage Renal Disease Clinical Trial using Kidney Transplant

University of Kansas - Recruiting 30 years to 70 years.
- Cognitive Impairment and Imaging Correlates in End Stage Renal Disease.
Kidney Transplant

Anemia in Chronic Kidney Disease in Non-dialysis Patients Clinical Trial using FG-4592; Placebo

Astellas Pharma Inc - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
FG-4592; Placebo

Chronic Kidney Disease Clinical Trial using Cholecalciferol

Federal University of Sao Paulo - Recruiting 18 years to 80 years.
- Impact of Treatment With Cholecalciferol on Immunological Markers in Patients With Hypovitaminosis D on Dialysis.
Cholecalciferol

Coronary Artery Disease, or Chronic Kidney Disease Clinical Trial

Chang Gung Memorial Hospital - Recruiting 18 years to 85 years.
- Clinical Feature and Outcome of Angiographic Coronary Artery Disease in Chronic Kidney Disease Patients.

Polycystic Kidney Disease Clinical Trial

Rockefeller University - Recruiting 18 years or older.
- Autosomal Dominant Polycystic Kidney Disease Data Repository.

Polycystic Liver Disease (PLD):, Polycystic Kidney, Autosomal Dom Clinical Trial using Ursodeoxycholic Acid

Radboud University - Recruiting 18 years to 80 years.
- An International, Multicenter, Randomized Controlled Clinical Trial Assessing the Efficacy of Ursodeoxycholic Acid as a Volume Reducing Treatment in Symptomatic Polycystic Liver Disease.
Ursodeoxycholic Acid

Renal Insufficiency, Chronic Clinical Trial

Universitaire Ziekenhuizen Leuven - Recruiting 18 years to 95 years.
- Study on Colonic Fermentation in Chronic Kidney Disease Patients.

Advanced Solid Tumors, Kidney Disease, or Renal Impairment Clinical Trial using AMG 386 + Paclitaxel; AMG 386

Amgen - Recruiting 18 years or older.
- An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects With Normal and Impaired Renal Function.
AMG 386 + Paclitaxel; AMG 386

Stage 5 Chronic Kidney Disease Clinical Trial using Multidisciplinary, intensive and collaborative care

National University, Singapore - Recruiting 21 years or older.
- Impact of a Multidisciplinary Intensive Management Clinic on Clinical, Patient-Reported and Economic Outcomes in Multi-Ethnic Asian Incident Hemodialysis Patients.
Multidisciplinary, intensive and collaborative care

Chronic Kidney Disease, or End-Stage Renal Disease Clinical Trial using Medication Information Transfer Intervention; Usual care for hospital discharge

Providence Medical Research Center - Recruiting 21 years or older.
- Medication Intervention in Transitional Care to Optimize Outcomes & Costs in CKD & ESRD.
Medication Information Transfer Intervention; Usual care for hospital discharge

Chronic Kidney Disease Clinical Trial using GCS-100; Placebo, Saline

La Jolla Pharmaceutical Company - Recruiting 18 years to 80 years.
- A Phase 2a, Placebo-Controlled, Randomized, Single-Blind Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease.
GCS-100; Placebo, Saline

Minimal Change Disease (MCD), Membranous Nephropathy, or Glomerul Clinical Trial

University of Michigan - Recruiting N/A or older.
- Nephrotic Syndrome Study Network Under the Rare Diseases Clinical Research Network.

Chronic Kidney Disease Clinical Trial using Vitamin D2 (ergocalciferol); Vitamin D3 (cholecalciferol)

University of Kansas - Recruiting 18 years or older.
- Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease.
Vitamin D2 (ergocalciferol); Vitamin D3 (cholecalciferol)

Somatostatin Analogs, Polycystic Liver Disease, Autosomal Dominan Clinical Trial using Pasireotide LAR; Placebo

Mayo Clinic - Recruiting 18 years or older.
- A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease.
Pasireotide LAR; Placebo

Kidney Failure, Chronic, or End Stage Renal Disease, Requiring Di Clinical Trial using NxStage System One

NxStage Medical - Recruiting 18 years or older.
- Comparison of Nocturnal Hemodialysis (NHD) and Short Daily Hemodialysis (DHD) With the NxStager System OneT.
NxStage System One

Chronic Kidney Disease (CKD), or End-Stage Renal Disease (ESRD) Clinical Trial

Los Angeles Biomedical Research Institute - Recruiting 18 years to 85 years.
- Malnutrition, Diet and Racial Disparities in Chronic Kidney Disease (CKD) - A Prospective Data Collection Study.

Kidney Diseases Clinical Trial using High/ Low Phosphate diet

University of British Columbia - Recruiting 19 years or older.
- Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease.
High/ Low Phosphate diet

Anemia Clinical Trial using FG-4592; Placebo

FibroGen - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis.
FG-4592; Placebo

Chronic Kidney Disease, or Hemodialysis Clinical Trial

Renal Research Institute - Recruiting 18 years to 88 years.
- Red Blood Cell Lifespan and Inflammation in Dialysis Patients.

Chronic Kidney Disease Clinical Trial using Kidney and/or Pancreas biopsy

University of Michigan - Recruiting N/A or older.
- Michigan Nephrology Research BioBank for Molecular Analysis of Renal Disease 'Nephrology Research BioBank'.
Kidney and/or Pancreas biopsy

Chronic Kidney Disease, Secondary Hyperparathyroidism (SHPT), or Clinical Trial using CTAP101 30 æg capsules; CTAP101 60 æg capsules; CTAP101 30 æg sugar pill capsule; CTAP101 60 æg sugar pill capsules

Cytochroma Inc. - Recruiting 18 years to 85 years.
- A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency.
CTAP101 30 æg capsules; CTAP101 60 æg capsules; CTAP101 30 æg sugar pill capsule; CTAP101 60 æg sugar pill capsules

Non-diabetic Chronic Kidney Disease, or Atherosclerosis Clinical Trial

Kocaeli Derince Education and Research Hospital - Recruiting 18 years to 75 years.
- The Relationship Between Serum Omentin-1 and IL-6 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease.

Chronic Kidney Disease Clinical Trial using AST-120

Seoul National University Hospital - Recruiting 18 years or older.
- K-STAR (Kremezin STudy Against Renal Disease Progression in Korea) Randomized, Open-label, Controlled Study.
AST-120

Cardiovascular Disease, Chronic Kidney Disease Patients, Hemodial Clinical Trial

China Medical University Hospital - Recruiting 20 years or older.
- L5 as a Risk Factor of Cardiovascular Disease in Chronic Kidney Disease and Dialysis Patients.

Chronic Disease, Kidney Diseases, or Cardiovascular Diseases Clinical Trial using rosiglitazone

Hospital Authority, Hong Kong - Recruiting 20 years to 75 years.
- Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients?.
rosiglitazone

Chronic Kidney Disease, or Obesity Clinical Trial using laparoscopic sleeve gastrectomy; weight management program

King's College Hospital NHS Trust - Recruiting 18 years or older.
- The Effect of Weight Loss Surgery on Preservation of Kidney Function and Cardiovascular Disease Risk Factors in Obese Patients With Stages 3-4 Chronic Kidney Disease: a Randomised Controlled Trial.
laparoscopic sleeve gastrectomy; weight management program

Chronic Kidney Disease Clinical Trial using Pharmacy care arm

San Francisco Veterans Administration Medical Center - Recruiting 18 years or older.
- Impact of a Pharmacist's Collaborative Management, Adherence,and Medication Education Program (CAMP) in an Ambulatory Renal Clinic.
Pharmacy care arm

Chronic Kidney Disease, or Hypertension Clinical Trial using Procedure: Regional phenylephrine arterial infusion

University of Michigan - Recruiting 18 years to 55 years.
- Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide.
Procedure: Regional phenylephrine arterial infusion